A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy

J Immunol. 2009 Aug 15;183(4):2837-50. doi: 10.4049/jimmunol.0804178. Epub 2009 Jul 27.

Abstract

Adoptive transfer of virus-specific T cells can treat infections complicating allogeneic hematopoietic cell transplants. However, autologous APCs are often limited in supply. In this study, we describe a panel of artificial APCs (AAPCs) consisting of murine 3T3 cells transduced to express human B7.1, ICAM-1, and LFA-3 that each stably express one of a series of six common HLA class I alleles. In comparative analyses, T cells sensitized with AAPCs expressing a shared HLA allele or autologous APCs loaded with a pool of 15-mer spanning the sequence of CMVpp65 produced similar yields of HLA-restricted CMVpp65-specific T cells; significantly higher yields could be achieved by sensitization with AAPCs transduced to express the CMVpp65 protein. T cells generated were CD8(+), IFN-gamma(+), and exhibited HLA-restricted CMVpp65-specific cytotoxicity. T cells sensitized with either peptide-loaded or transduced AAPCs recognized epitopes presented by each HLA allele known to be immunogenic in humans. Sensitization with AAPCs also permitted expansion of IFN-gamma(+) cytotoxic effector cells against subdominant epitopes that were either absent or in low frequencies in T cells sensitized with autologous APCs. This replenishable panel of AAPCs can be used for immediate sensitization and expansion of virus-specific T cells of desired HLA restriction for adoptive immunotherapy. It may be of particular value for recipients of transplants from HLA-disparate donors.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles*
  • Animals
  • Cells, Cultured
  • Cytomegalovirus / immunology*
  • Epitopes, T-Lymphocyte / immunology
  • HLA-A Antigens / genetics
  • HLA-A2 Antigen
  • HLA-A24 Antigen
  • HLA-A3 Antigen
  • HLA-B Antigens / genetics
  • HLA-B7 Antigen
  • HLA-B8 Antigen
  • Histocompatibility Antigens Class I / biosynthesis
  • Histocompatibility Antigens Class I / genetics*
  • Humans
  • Immunodominant Epitopes / administration & dosage
  • Immunodominant Epitopes / immunology*
  • Immunotherapy, Adoptive*
  • Lymphocyte Activation / immunology*
  • Mice
  • NIH 3T3 Cells
  • Phosphoproteins / administration & dosage
  • Phosphoproteins / immunology*
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / transplantation
  • T-Lymphocyte Subsets / virology
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*
  • T-Lymphocytes, Cytotoxic / virology
  • Viral Matrix Proteins / administration & dosage
  • Viral Matrix Proteins / immunology*

Substances

  • Epitopes, T-Lymphocyte
  • HLA-A Antigens
  • HLA-A*02:01 antigen
  • HLA-A*03:01 antigen
  • HLA-A*24:02 antigen
  • HLA-A2 Antigen
  • HLA-A24 Antigen
  • HLA-A3 Antigen
  • HLA-B Antigens
  • HLA-B*07:02 antigen
  • HLA-B*08:01 antigen
  • HLA-B7 Antigen
  • HLA-B8 Antigen
  • Histocompatibility Antigens Class I
  • Immunodominant Epitopes
  • Phosphoproteins
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa